OBJECTIVE: To review the epidemiologic studies that describe the relationships among diabetes, obesity, and cancer; animal studies that have helped to decipher the mechanisms of cancer development; and some of the therapeutic targets undergoing investigation. METHODS: An electronic search was performed of Medline, Scopus, Google Scholar, and ClinicalTrials.gov to identify English-language articles and studies published from 1995 through 2010 relating to obesity, insulin, insulinlike growth factors, diabetes mellitus, and cancer. RESULTS: Epidemiologic studies have reported that diabetes and obesity are linked to an increased risk of certain cancers in association with higher levels of insulin, C-peptide, and insulinlike growth factor 1. Animal models have demonstrated that increased insulin, insulinlike growth factor 1, and insulinlike growth factor 2 signaling can enhance tumor growth, while inhibiting this signaling can reduce tumorigenesis. Therapies that target insulin and insulinlike growth factor 1 signaling pathways have been developed and are currently in clinical trials to treat cancer. CONCLUSIONS: Insulin, insulinlike growth factor 1, and insulinlike growth factor 2 signaling through the insulin receptor and the insulinlike growth factor 1 receptor can induce tumorigenesis, accounting to some extent for the link between diabetes, obesity, and cancer. Knowledge of these pathways has enhanced our understanding of tumor development and allowed for the discovery of novel cancer treatments.
OBJECTIVE: To review the epidemiologic studies that describe the relationships among diabetes, obesity, and cancer; animal studies that have helped to decipher the mechanisms of cancer development; and some of the therapeutic targets undergoing investigation. METHODS: An electronic search was performed of Medline, Scopus, Google Scholar, and ClinicalTrials.gov to identify English-language articles and studies published from 1995 through 2010 relating to obesity, insulin, insulinlike growth factors, diabetes mellitus, and cancer. RESULTS: Epidemiologic studies have reported that diabetes and obesity are linked to an increased risk of certain cancers in association with higher levels of insulin, C-peptide, and insulinlike growth factor 1. Animal models have demonstrated that increased insulin, insulinlike growth factor 1, and insulinlike growth factor 2 signaling can enhance tumor growth, while inhibiting this signaling can reduce tumorigenesis. Therapies that target insulin and insulinlike growth factor 1 signaling pathways have been developed and are currently in clinical trials to treat cancer. CONCLUSIONS:Insulin, insulinlike growth factor 1, and insulinlike growth factor 2 signaling through the insulin receptor and the insulinlike growth factor 1 receptor can induce tumorigenesis, accounting to some extent for the link between diabetes, obesity, and cancer. Knowledge of these pathways has enhanced our understanding of tumor development and allowed for the discovery of novel cancer treatments.
Authors: Stephen D Hursting; John Digiovanni; Andrew J Dannenberg; Maria Azrad; Derek Leroith; Wendy Demark-Wahnefried; Madhuri Kakarala; Angela Brodie; Nathan A Berger Journal: Cancer Prev Res (Phila) Date: 2012-10-03
Authors: Ruth E Patterson; Graham A Colditz; Frank B Hu; Kathryn H Schmitz; Rexford S Ahima; Ross C Brownson; Kenneth R Carson; Jorge E Chavarro; Lewis A Chodosh; Sarah Gehlert; Jeff Gill; Karen Glanz; Debra Haire-Joshu; Karen Louise Herbst; Christine M Hoehner; Peter S Hovmand; Melinda L Irwin; Linda A Jacobs; Aimee S James; Lee W Jones; Jacqueline Kerr; Adam S Kibel; Irena B King; Jennifer A Ligibel; Jeffrey A Meyerhardt; Loki Natarajan; Marian L Neuhouser; Jerrold M Olefsky; Enola K Proctor; Susan Redline; Cheryl L Rock; Bernard Rosner; David B Sarwer; J Sanford Schwartz; Dorothy D Sears; Howard D Sesso; Meir J Stampfer; S V Subramanian; Elsie M Taveras; Julia Tchou; Beti Thompson; Andrea B Troxel; Marianne Wessling-Resnick; Kathleen Y Wolin; Mark D Thornquist Journal: Cancer Causes Control Date: 2013-02-03 Impact factor: 2.506
Authors: P Blin; R Lassalle; C Dureau-Pournin; B Ambrosino; M A Bernard; A Abouelfath; H Gin; C Le Jeunne; A Pariente; C Droz; N Moore Journal: Diabetologia Date: 2012-01-06 Impact factor: 10.122